Bristol-Myers Squibb (BMY) Tops Q3 EPS by 4c; Boosts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Bristol-Myers Squibb Reports Third Quarter Financial Results
October 27, 2015 6:59 AM EDTIncreases Revenues 4% to $4.1 Billion Posts Third Quarter GAAP EPS of $0.42 and Non-GAAP EPS of $0.39 Achieves Significant U.S. Regulatory and Clinical Milestones in Immuno-Oncology Opdivo Approved for Previously-Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Regardless of PD-L1 Expression Opdivo-Yervoy Regimen Approved for Metastatic Melanoma Opdivo Granted Breakthrough Therapy Designation for Metastatic Renal Cell Carcinoma Refines 2015 GAAP EPS Guidance Range to $1.02 - $1.07... More
